| Date | Title | Description |
| 09.08.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BAYA, RCFA, OBDC, GTHX on Behalf of Shareholders | NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relat... |
| 01.05.2024 | G1 Therapeutics and Pepper Bio Ink Global License Agreement for Lerociclib | What You Should Know:
– G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding the As... |
| 09.02.2023 | First Prescription for COSELA® (trilaciclib) Issued in China | - COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital on January 28, 2023
- Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription
NANJING, China... |
| 08.02.2022 | Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding | Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the closing of a US$50 million, t... |
| 16.12.2021 | G1 Therapeutics : Announces Expansion of COSELA (Trilaciclib) Sales Force - Form 8-K | G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
- G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement -
- Management to Host Webcast and Conference Call today at 8:30 AM ET -
RESEARCH TRIANGLE P... |
| 03.11.2021 | G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights - Form 8-K | G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
- Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -
- Announced Supplemental COSELA S... |
| 01.10.2021 | G1 Therapeutics : Announces Permanent J-Code from Centers for Medicare and Medicaid Services | RESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July... |
| 16.09.2021 | G1 THERAPEUTICS : ANNOUNCES NEW SUPPLEMENTAL COSELA (TRILACICLIB) SALES FORCE | RESEARCH TRIANGLE PARK, N.C. - G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, announced that it will hire and train a 15-person oncology sales force to supplement the Boehringer Ingelheim oncology commercial team... |
| 15.09.2021 | G1 Therapeutics : Announces New Supplemental COSELA (Trilaciclib) Sales Force (Form 8-K) | G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
- New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities -
RESEARCH TRIANGLE PARK, NC, September 15, 2021 - G1 Therapeutics, Inc. (Nasdaq:... |
| 15.09.2021 | G1 Therapeutics : Announces New Supplemental COSELA™ (Trilaciclib) Sales Force | RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person oncology sales force to supplement the Boehr... |
| 26.04.2021 | G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer | – Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Laboratory Values, and Use of Supportive Ca... |
| 21.04.2021 | Rhythm Therapeutics, Inc. Awarded $3.67 million NIH SBIR Fast Track Grant to Develop Gene Therapy for Atrial Fibrillation | Rishi Arora, MD, FHRS, FAHA “AF is the most common heart rhythm disorder, affecting six million people in the US and 33 million worldwide,” said Dr. Rishi Arora, CEO of Rhythm Therapeutics and Professor of Medicine, Clinical Cardiac Electro... |
| 10.12.2020 | Lumira co-leads $12.8 Million raise in Cyrano Therapeutics | Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy for smell and flavor restoration, has raised $12.8 million in a Series A financing led by Remiges Ventures and Lumira Ventures, with t... |
| 17.08.2020 | G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer | – PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration
– Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits
– G1 launchin... |
| 13.03.2020 | G1 Therapeutics Strengthens Executive Team & Board of Directors | RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Office... |
| 26.02.2020 | G1 Therapeutics Provides Q4 & Fiscal Year 2019 Update | RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2019. |
| 15.01.2020 | G1 Therapeutics & Quantum Leap Healthcare Collaborate in Breast Cancer Research Study | SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy des... |
| 11.12.2019 | G1 Therapeutics Presents Additional Efficacy Data from Clinical Trial | RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibi... |
| 30.09.2019 | G1 Therapeutics presents data from Phase 2 mTNBC trial for trilaciclib at ESMO19 | RESEARCH TRIANGLE PARK, N.C. and BARCELONA, Spain, Sept. 28, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported preliminary overall survival (OS) data from the company’s randomize... |
| 08.08.2019 | FDA Grants G1 Therapeutics Breakthrough Therapy Designation & Provides Q2 2019 Financial Update | Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update |
| 30.07.2019 | Former Pfizer VP Joins G1 Therapeutics as Chief Business Officer | Related Article: G1 Therapeutics Appoints Garry Nicholson to Chair of the Board of Directors |
| 18.06.2019 | Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy | – Detailed data from this trial will be presented at a medical meeting later this year – |
| 13.06.2019 | G1 Therapeutics Appoints Garry Nicholson to Chair of the Board of Directors | – Garry Nicholson to serve as new board chair –
– Sir Andrew Witty, Fredric Eshelman, Pharm.D. and prior chair Seth Rudnick, M.D. re-elected – |
| 01.06.2019 | New Patient-Reported Outcomes Data Shows Trilaciclib Improves Chemotherapy Experience for Patients | G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a randomized Phase 2 clinical trial demonstrating the myelopreservation benefits of trilaciclib in patients undergoing chemoth... |
| 30.04.2019 | G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020 | Research Triangle Park, N.C., April 29, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a regulatory update on trilaciclib, a first-in-class myelopreservation agent designed to... |
| 12.03.2018 | G1 Therapeutics Announces Closing of Offering of Common Stock | RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 shares of its common stock a... |
| 18.05.2017 | Term Sheet — Thursday, May 18 | DOING THEIR OWN THING
It’s fairly normal for successful venture capital pros to spend their careers building up a track record at a larger firm, and then “spin off” with their own firms. Lately, as limited partner interest in venture contin... |
| 17.05.2017 | Term Sheet — Wednesday, May 17 | VALUE ADD, AMAZON, CYBER-CORN
In which Mark Cuban trolls venture capitalists: At the Lerer Ventures CEO Summit yesterday, Shark Tank star Mark Cuban was asked if he believes artificial intelligence will disrupt the business of venture capit... |
| 09.05.2017 | Term Sheet — Tuesday, May 9 | PROFITABILITY OVER PASSION
Land of Opportunity: Yesterday’s Term Sheet included a link to this story about SoftBank’s ambitions in India that deserves a little more attention. Like so many articles about tech in India, this one draws compar... |
| 17.04.2017 | Term Sheet — Monday, April 17 | EXUBERANT DEALMAKING
Good morning!
Paid Content You can't secure what you can't see From ExtraHop
But it may also be a convenient excuse when Chinese buyers get cold feet, as Variety noted last month. It’s even true of LeEco. It’s no secret... |
| 12.05.2016 | G1 Therapeutics Completes $47M Series C Funding | G1 Therapeutics, Inc., a Research Triangle Park, NC-based clinical-stage oncology company, completed a $47m Series C funding.
The round was led by Cormorant Asset Management with participation from new investors Aju IB Investment, Cowen Pri... |
| 11.05.2016 | G1 Therapeutics Secures $47 Million Series C Financing | G1 Therapeutics Secures $47 Million Series C Financing |
| 26.02.2016 | Chromis Therapeutics Inc. Raises $3 Million in Seed Round | Chromis Therapeutics Inc., an antiviral drug discovery company in San Diego, has raised $3 million in a seed financing round led by Torrey Pines Investment.
Chromis will use the funds to advance its platform of antiviral drugs, including a ... |
| 05.02.2015 | G1 Therapeutics Raises $33 Million in Series B Financing | G1 Therapeutics Raises $33 Million in Series B Financing |
| 16.10.2013 | G1 Therapeutics Raises $12.5M in Series A |
CHAPEL HILL, NC, G1 Therapeutics announced that it has raised a Series A financing of $12.5M.
>> Click here for more funding data on G1 Therapeutics
>> To export G1 Therapeutics funding data to PDF and Excel, click here
G... |
| 16.10.2013 | G1 Therapeutics Raises $12.5M in Series A Financing | G1 Therapeutics, Inc., Chapel Hill, NC-based pharmaceutical company that focuses on the discovery and development of novel small molecules for use in cancer therapy and biodefense applications, raised $12.5M in Series A financing.
The round... |
| 01.05.2013 | G1 Therapeutics developing treatment to protect soldiers, chemo patients from radiation damage | The team is working on two formulations of the same molecule. The lead formulation is in intravenous form that could be added to existing chemo treatments.
“This allows us to exquisitely tune in the dose and to turn it on or turn it off,” C... |
| 07.01.2013 | $125M early stage fund seeks to invest in health startups in N.C. and southeastern U.S. | The HVP IV fund also established a HVP IV SBIC, which is the first licensee of the U.S. Small Business Administration’s (SBA) newly established Early Stage SBIC Program.
An earlier, initial closing of the HPV IV fund in 2011 led to the esta... |
| 16.10.2012 | Seed round will help radiation therapy startup prevent harmful effects of chemotherapy | Jay Strum, president of G1 Therapeutics (formerly G-Zero Therapeutics), said the company’s seed round was led by RTP venture firm Hatteras Ventures and will be used to move the radiation therapy drug toward IND-enabling studies, with the ho... |
| - | Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 | SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, s... |
| - | Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 | SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million... |
| - | G1 Therapeutics developing treatment to protect soldiers, chemo patients from radiation damage | After the Boston Marathon bombing, it’s easy to understand why the government is giving G1 Therapeutics millions of dollars to develop a pill that protects against radiation exposure.
If the pressure-cooker bomb had been a dirty bomb instea... |
| - | $125M early stage fund seeks to invest in health startups in N.C. and southeastern U.S. | Hatteras Venture Partners announced Monday that the company has closed its fourth fund totaling $125 million.
The Durham, North Carolina-based venture capital firm invests in device, diagnostic, biopharma, health IT and human-health related... |
| - | Seed round will help radiation therapy startup prevent harmful effects of chemotherapy | One of the most common and most disruptive drawbacks of existing cancer chemotherapies is the toxic effect of bone marrow suppression that can result from a patient’s exposure to ionized radiation.
The loss of red blood cells, white blood c... |
